Clinical trial · Observational
Three-Dimensional Fluoroscopic Guidance During Transbronchial Cryobiopsy
Three-Dimensional Fluoroscopic Guidance During Transbronchial Cryobiopsy, a Prospective Pilot Study
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
This study assesses the effectiveness of transbronchial cryobiopsy guided by 3-dimensional fluoroscopy. Transbronchial cryobiopsy is a procedure to collect lung tissue. The main side effect seen after a transbronchial cryobiopsy is pneumothorax (air leaking out of the lung, which may cause a completely or partially collapsed lung). The standard imaging scans used during this procedure are 2-dimensional (like a photo), which can make it difficult for the doctor to know exactly where the biopsy tool is during the procedure. If the exact location of the device is not clear, a patient can be at a higher risk of pneumothorax. Using a 3-dimensional imaging technique may help to decrease the risk of pneumothorax during transbronchial cryobiopsy.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Lung Carcinoma | Lung Carcinoma | ONTOLOGY_EXACT | 0.98 |
Interventions
Interventions (2)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Electronic Health Record Review | Other | — | UNRESOLVED |
| Transbronchial Cryobiopsy Guided by Three-Dimensional Fluoroscopy | Procedure | — | UNRESOLVED |
Design
Arms and outcomes
Arms (1)
- label
- Observational (transbronchial cryobiopsy)
- description
- Patients undergo transbronchial cryobiopsy guided by three-dimensional fluoroscopy. Patients' medical records are also reviewed.
- interventionNames
- Other: Electronic Health Record Review
- Procedure: Transbronchial Cryobiopsy Guided by Three-Dimensional Fluoroscopy
Primary outcomes (1)
- measure
- Incidence of pneumothorax
- timeFrame
- Up to 72 hours after cryobiopsy
- description
- The proportion of patients developing pneumothorax will be compared with the proportion in the historical control (i.e., 20%) using two-sided binomial test. A p-value of less than 0.05 will indicate a statistical significance. The proportion of patients identified as developing pneumothorax and its exact 95% confidence interval will be estimated. Poisson regression model will be used to estimate the incidence of pneumothorax accounting for the number of biopsy sites.
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * Age 18 years or older * Presence of an intraparenchymal lung lesion for which cryobiopsy is deemed the most appropriate method of biopsy * Ability to provide informed consent Exclusion Criteria: * Acute respiratory failure (defined as oxygen requirement \> 4 L/min by nasal cannula above baseline, or need for any intervention to support ventilation and/or gas exchange for any duration, including invasive and non-invasive positive pressure ventilation, high-flow therapy, non-rebreather mask, or Venturi mask) * Intensive care unit (ICU) admission * Forced vital capacity (FVC) \< 50% or diffusing capacity of the lung for carbon monoxide (CO) (DLCO) \< 35% (if pulmonary function tests are available) * Known or suspected pulmonary hypertension (defined as elevated right ventricular systolic pressure on echocardiogram, if available) * Acute renal failure or chronic kidney disease * Platelets \< 100,000/uL * International normalized ratio (INR) \> 1.5 * Use of anticoagulant therapy that cannot be held for 2 days * Use of antiplatelet therapy (other than baby aspirin) that cannot be held for 5 days * Any bleeding diathesis * Pregnancy
References
Publications (0)
Data not yet available